CSBio CSBio

X
[{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Taiwan Liposome Company"},{"orgOrder":0,"company":"Taiwan Liposome Company","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 \u2013 Inhalable Liposome Formulations of Antiviral Drugs for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Taiwan Liposome Company"},{"orgOrder":0,"company":"Medigen Vaccine Biologics","sponsor":"Dynavax Technologies","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medigen's COVID-19 Vaccine Combined with Dynavax's CpG 1018 Adjuvant Receives Taiwan Government Subsidy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Medigen Vaccine Biologics"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma Received IND Approval from China NMPA for UB-621 Phase 2 Trial in Patients with Recurrent Genital Herpes","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"United BioPharma"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Shanghai Public Health Clinical Centre","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"United BioPharma, Shanghai Public Health Clinical Centre and Cheng Kung University Partner on World's First Long-acting Herpes Treatment UB-621","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"United BioPharma"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiGen Filed U.S IND for Its Influenza Antiviral TG-1000","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"TaiGen Biotechnology"},{"orgOrder":0,"company":"TaiGen Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"TAIWAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"TaiGen Biotechnology"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            UB-621 is a first-in-class anti-gD mAb a best-in-class long-acting treatment for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and HSV2).

            Lead Product(s): UB-621

            Therapeutic Area: Infections and Infectious Diseases Product Name: UB-621

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Shanghai Public Health Clinical Centre

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 18, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            GS-441524 (named ISPM21) is main plasma metabolite of the antiviral prodrug remdesivir. Studies on inhalable liposomal ISPM21 showed significantly higher concentrations in the lungs than their conventional counterparts.

            Lead Product(s): ISPM21

            Therapeutic Area: Infections and Infectious Diseases Product Name: GS-441524

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 23, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The current Phase 2 study is a randomized, single-blinded, placebo-controlled study to investigate the efficacy and safety of single dose UB-621 treatment for recurrent genital herpes.

            Lead Product(s): UB-621

            Therapeutic Area: Infections and Infectious Diseases Product Name: UB-621

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 11, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.

            Lead Product(s): TG-1000

            Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 02, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In preclinical studies, TLC19 demonstrated 30-fold exposure in the lungs while achieving lower blood and heart exposure than oral HCQ and unformulated HCQ.

            Lead Product(s): Hydroxychloroquine Sulphate

            Therapeutic Area: Infections and Infectious Diseases Product Name: TLC19

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The first participant in MVC's Phase 1 clinical trial was dosed with MVC's COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant at National Taiwan University Hospital in early October.

            Lead Product(s): S-2P vaccine,CpG 1018

            Therapeutic Area: Infections and Infectious Diseases Product Name: S-2P vaccine

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Dynavax Technologies

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses.

            Lead Product(s): TG-1000

            Therapeutic Area: Infections and Infectious Diseases Product Name: TG-1000

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 05, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY